Editorials in 2016

Despite an increasingly strident outcry against drug prices in the United States, manufacturers likely face an evolution in the reimbursement landscape, rather than a revolution.

The US Food and Drug Administration approved a muscular-dystrophy drug against the scientific advice of its own staff and advisors. Despite leadership's attempts to downplay the controversy, doubts now surround standards for accelerated approval.

Microbiologists are poised to embrace heterogeneity through the use of single-cell technologies.

Although a US law mandating disclosure of GM ingredients provides food companies with a way out of the labeling rabbit hole, appeasing the anti-GM movement will likely backfire.

The rapid growth of private clinics touting unproven stem cell therapies warrants increased regulatory scrutiny and better tracking of patient outcomes.

Following the bombshell UK vote to leave the EU, Nature Biotechnology offers some cheer to the UK's former life sciences chief, George Freeman.

Headlines about a proposal to engineer an entirely synthetic human genome largely missed the point.

A drug company executive thinks academic institutions should give money back for research that turns out to be 'irreproducible'.

A House panel's witch hunt against fetal tissue research demands a forceful response from the biomedical community.

Nature Biotechnology will now publish all computational biology papers in its research section, a decision that reflects an ongoing need to break down silos surrounding mathematical, computational and basic biology.

The biotech community has made remarkable progress over the past 20 years. Now it needs to break out of its bubble.

Some biotech companies now eschew traditional publication in peer-reviewed journals. Does it matter?

Will targeted immunosuppressants and new tools in genome engineering be enough to finally give xenopigs wings?